A Single-Dose, Bioequivalence and Food Effect Bioavailability Study in Healthy Volunteers Comparing the Commercial Lumacaftor 200 mg / Ivacaftor 125 mg Combination Film-Coated Tablet (Orkambi®) to the Lumacaftor 200 mg Film-Coated Tablet Formulation, and the Lumacaftor 200 mg Film-Coated Tablet Formulation in the Fasted to Fed State
Latest Information Update: 28 Dec 2023
At a glance
- Drugs Lumacaftor (Primary) ; Ivacaftor/lumacaftor
- Indications Heart failure; Subarachnoid haemorrhage
- Focus Pharmacokinetics
- Sponsors Qanatpharma
Most Recent Events
- 22 Dec 2023 Status changed from recruiting to completed.
- 17 Oct 2023 New trial record
- 16 Oct 2023 Planned End Date changed from 1 Nov 2023 to 1 Dec 2023.